Home > Boards > US Listed > Medical - Healthcare > CorMedix Inc (CRMD)

The FDA has granted priority review for Defencath™

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Expresso123 Member Profile
 
Followed By 8
Posts 926
Boards Moderated 0
Alias Born 07/04/17
160x600 placeholder
CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Progra... GlobeNewswire Inc. - 6/10/2021 8:30:00 AM
CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference GlobeNewswire Inc. - 6/9/2021 8:30:00 AM
CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc. - 5/27/2021 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 4:47:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2021 4:19:15 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/20/2021 4:17:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/19/2021 5:41:04 PM
CorMedix slumps 20% despite a surge in Q1 revenue Seeking Alpha - 5/14/2021 3:34:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2021 6:03:51 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 4:37:20 PM
CorMedix EPS misses by $0.02, beats on revenue Seeking Alpha - 5/13/2021 4:23:02 PM
CorMedix names Thomas Nusbickel chief commercial officer Seeking Alpha - 5/13/2021 8:45:40 AM
CorMedix Inc. Announces Appointment of Chief Commercial Officer GlobeNewswire Inc. - 5/13/2021 8:30:00 AM
CorMedix Inc. to Participate at the 7th Annual Truist Securities Life Sciences Summit GlobeNewswire Inc. - 4/28/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/15/2021 10:04:26 AM
CorMedix meets FDA to resolve issues in CRL for DefenCath Seeking Alpha - 4/14/2021 9:28:56 AM
CorMedix Has Meeting With FDA on DefenCath Catheter Lock Solution NDA GlobeNewswire Inc. - 4/14/2021 9:00:00 AM
CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire Inc. - 4/7/2021 8:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/30/2021 5:05:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/30/2021 5:04:06 PM
CorMedix EPS beats by $0.03, beats on revenue Seeking Alpha - 3/30/2021 4:07:54 PM
CorMedix Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 3/30/2021 4:05:00 PM
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program GlobeNewswire Inc. - 3/15/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2021 4:43:32 PM
CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations... GlobeNewswire Inc. - 3/11/2021 8:30:00 AM
Expresso123   Wednesday, 02/24/21 05:21:12 PM
Re: None
Post # of 2443 
The FDA has granted priority review for Defencath™ and has set a Prescription Drug User Fee Act (PDUFA) date of February 28, 2021

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences